54741_Image_jpeg.jpg
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
June 27, 2022 08:00 ET | Daxor Corporation
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...
54741_Image_jpeg.jpg
Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting
June 13, 2022 08:00 ET | Daxor Corporation
Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American...
54741_Image_jpeg.jpg
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
May 25, 2022 08:00 ET | Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
May 12, 2022 08:00 ET | Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
May 02, 2022 08:00 ET | Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
54741_Image_jpeg.jpg
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
April 06, 2022 08:00 ET | Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 08:00 ET | Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
March 01, 2022 09:00 ET | Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
54741_Image_jpeg.jpg
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
March 01, 2022 08:00 ET | Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...
54741_Image_jpeg.jpg
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
February 17, 2022 08:00 ET | Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...